Your browser doesn't support javascript.
loading
Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: Preliminary findings.
Hoogland, Aasha I; Jim, Heather S L; Gonzalez, Brian D; Small, Brent J; Gilvary, Danielle; Breen, Elizabeth C; Bower, Julienne E; Fishman, Mayer; Zachariah, Babu; Jacobsen, Paul B.
Afiliação
  • Hoogland AI; Moffitt Cancer Center, Tampa, Florida.
  • Jim HSL; Moffitt Cancer Center, Tampa, Florida.
  • Gonzalez BD; Moffitt Cancer Center, Tampa, Florida.
  • Small BJ; University of South Florida, Tampa, Florida.
  • Gilvary D; Moffitt Cancer Center, Tampa, Florida.
  • Breen EC; University of California Los Angeles, Los Angeles, California.
  • Bower JE; University of California Los Angeles, Los Angeles, California.
  • Fishman M; Moffitt Cancer Center, Tampa, Florida.
  • Zachariah B; James A. Haley Veterans Affairs' Medical Center, Tampa, Florida.
  • Jacobsen PB; National Cancer Institute, Bethesda, Maryland.
Cancer ; 127(9): 1476-1482, 2021 05 01.
Article em En | MEDLINE | ID: mdl-33378113
BACKGROUND: Increases in fatigue, depressive symptomatology, and cognitive impairment are common after the initiation of androgen deprivation therapy (ADT) for prostate cancer. To date, no studies have examined the potential role of inflammation in the development of these symptoms in ADT recipients. The goal of the current study was to examine circulating markers of inflammation as potential mediators of change in fatigue, depressive symptomatology, and cognitive impairment related to the receipt of ADT. METHODS: Patients treated with ADT for prostate cancer (ADT+; n = 47) were assessed around the time of the initiation of ADT and 6 and 12 months later. An age- and education-matched group of men without a history of cancer (CA-; n = 82) was assessed at comparable time points. Fatigue, depressive symptomatology, and cognitive impairment were assessed with the Fatigue Symptom Inventory, the Center for Epidemiological Studies Depression Scale, and a battery of neuropsychological tests, respectively. Circulating markers of inflammation included interleukin 1 receptor antagonist (IL-1RA), interleukin 6 (IL-6), soluble tumor necrosis factor receptor II (sTNF-RII), and C-reactive protein (CRP). RESULTS: Fatigue, depressive symptomatology, and serum IL-6 increased significantly over time in the ADT+ group versus the CA- group; rates of cognitive impairment also changed significantly between the groups. No significant changes in IL-1RA, sTNF-RII, or CRP over time were detected. Treatment-related increases in IL-6 were associated with worsening fatigue but not depressive symptomatology or cognitive impairment. CONCLUSIONS: Results of this preliminary study suggest that increases in circulating IL-6, perhaps due to testosterone inhibition, may play a role in fatigue secondary to receipt of ADT. Additional research is needed to determine whether interventions to reduce circulating inflammation improve fatigue in this population.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Mediadores da Inflamação / Antineoplásicos Hormonais / Antagonistas de Androgênios / Inflamação Tipo de estudo: Diagnostic_studies / Etiology_studies Limite: Aged / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Mediadores da Inflamação / Antineoplásicos Hormonais / Antagonistas de Androgênios / Inflamação Tipo de estudo: Diagnostic_studies / Etiology_studies Limite: Aged / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article